Both in Biotechnology
X4 Pharmaceuticals vs SAB Biotherapeutics
Over the past year XFOR returned −18.4% and SABS returned −2.2%; their daily moves had a correlation of 0.26.
XFOR −18.4% SABS −2.2%Growth of $1, one year, split-adjusted
| Metric | XFOR | SABS |
|---|---|---|
| Price | $3.24 | $3.18 |
| Market cap | $321.2M | $289.3M |
| Today | +2.21% | +1.92% |
| 1 month | +17.0% | +8.5% |
| 6 months | −26.0% | −16.3% |
| Year to date | −19.0% | −15.0% |
| 1 year | −20.8% | −2.2% |
| Revenue growth (YoY) | +346.3% | — |
| Gross margin | 81.6% | — |
| Net margin | −183.5% | — |
| P/E (TTM) | — | — |
| Price / sales | 20.3× | — |
| Net cash | $131.2M | $99.4M |
| Dividend yield | — | — |
| Volatility (60d) | 60.9% | 56.6% |
| Short % of float | 9.3% | 6.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).